J&J Q3 2026 sales rise 5.9% to $25.4B, but talc charge cuts GAAP EPS to $0.09
Johnson & Johnson raised its full-year 2026 sales and adjusted EPS guidance, driven by 7.7% growth in its Innovative Medicine segment. However, a massive one-time talc litigation charge dragged GAAP net earnings down…